Weiss Multi Strategy Advisers LLC maintained its position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 37,500 shares of the medical device company’s stock at the end of the first quarter. Weiss Multi Strategy Advisers LLC owned 0.11% of AtriCure worth $718,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Montreal Can increased its position in shares of AtriCure by 1.2% in the first quarter. Bank of Montreal Can now owns 10,462 shares of the medical device company’s stock valued at $200,000 after buying an additional 128 shares during the last quarter. Bayesian Capital Management LP purchased a new position in AtriCure during the fourth quarter valued at about $204,000. Rockefeller Financial Services Inc. increased its position in AtriCure by 185.0% in the first quarter. Rockefeller Financial Services Inc. now owns 11,766 shares of the medical device company’s stock valued at $225,000 after buying an additional 7,637 shares in the last quarter. Tudor Investment Corp Et Al purchased a new position in AtriCure during the fourth quarter valued at about $253,000. Finally, Vident Investment Advisory LLC purchased a new position in AtriCure during the first quarter valued at about $323,000. 86.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of AtriCure, Inc. (ATRC) traded up 0.94% during mid-day trading on Friday, hitting $23.55. 54,943 shares of the company’s stock traded hands. The company’s market cap is $799.43 million. AtriCure, Inc. has a 52 week low of $13.45 and a 52 week high of $23.95. The firm has a 50-day moving average of $21.58 and a 200 day moving average of $19.06.
AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, May 4th. The medical device company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $41.30 million for the quarter, compared to analyst estimates of $40.25 million. AtriCure had a negative net margin of 21.07% and a negative return on equity of 19.89%. AtriCure’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.31) earnings per share. Equities research analysts predict that AtriCure, Inc. will post ($0.96) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/06/23/weiss-multi-strategy-advisers-llc-holds-stake-in-atricure-inc-atrc.html.
ATRC has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of AtriCure in a report on Wednesday, March 1st. BTIG Research downgraded AtriCure from a “buy” rating to a “neutral” rating in a report on Monday, March 6th. Northland Securities reaffirmed a “buy” rating and set a $24.00 price objective on shares of AtriCure in a report on Monday, March 20th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price objective on shares of AtriCure in a report on Monday, April 17th. Finally, Zacks Investment Research raised AtriCure from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a report on Tuesday, May 9th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $23.56.
In other news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $21.44, for a total transaction of $214,400.00. Following the transaction, the director now owns 24,162 shares in the company, valued at $518,033.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.00% of the stock is currently owned by insiders.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.